Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vofatamab + Pembrolizumab in Advanced Urothelial Carcinoma
NCT03123055Phase 2Terminated
- Sponsor
- Rainier Therapeutics
- Start
- Apr 2017
- Primary completion
- Dec 2019
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 17
01
Overview
Phase 2, open-label, single-arm trial of vofatamab in urothelial carcinoma (UC), sponsored by Rainier Therapeutics. Primary endpoints: Dose Limiting Toxicities at 35 days, Adverse Events at 2.5 years and 1 more. Started Apr 2017; status: terminated.
02
Drugs
vofatamab
03
Conditions
urothelial carcinoma (UC)
Beyond the preview
Go deeper on NCT03123055.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03123055.